Biotech Specialty Pharma

Genomic Expression Inc

69 Tiemann Pl
New York, NY 10027 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Digital array for biomarker discovery.

Management Gitte L. Pedersen, CEO, Co-Founder; Jesper Zeuthen, D.Sc., President; Morten L. Pedersen, CTO, founder; Jan Lomholdt, CBO tools; Paul Rohricht, CBO diagnostics;

Click here for Financial Data
Keywords: genomics, digital array, DNA barcode, Denmark, discovery tools, genome, detection tools, diagnostics, gene chip, gene array, next generation sequencing.Allergy, Cardiology, Dermatology, Diabetes, Diagnostics, Gastroenterology, HIVAIDS, Immunology, Infectious Disease, Neurology, Obesity, Oncology, PatientMonitoring, Software Systems, WoundCare, Healthcare IT, GCC Member


Updated: Jun. 10, 2019


Genomic Expression develops proprietary cost-effective genomics diagnostics tools for personalized medicine in order to increase the effectiveness of research and delivery of healthcare. The Company......view more

Products / Services

Genomic Expression is launching a first generation digital array to key universities and corporations. In addition to this the company is exploring various deal opportunities including: 1) Applying t......view more

Technology / Differentiation

Genomic Expression's DATA platform enjoys a cost and performance advantage over current gene arrays. DATA abbreviates the process of developing diagnostics for Personalized Medicine, because it can be...view more

Market / Customers

Genomic Expression has initiated projects with strategic partners such as New York University, Columbia University, The National Cancer Institute, Harvard Partners, The John F. Kennedy Institute, Cope......view more

Competitors / Substitutes / Alternatives

Largest genomic tool provides include: Affymetrix, Illumina, Agilent, Nimblegen/Roche and Life Technologies. Largest genomics pronostic/diagnostic providers include: Genomic Health, Myriad, Gen- Probe...view more


It is Genomic Expressions exit strategy to get acquired. Any of the current array providers; Affymetrix, Agilent or Nimblegen/Roche are very likely exit opportunities, in addition to all the other gen...view more

Revenue / Funding

Genomic Expression is raising $1 mill now to market out first generation digital array, advance our IP, prepare for production, for a series A/and or exit....view more


First generation products are commercially and ready to launch. The technology can be further scaled to enable the interrogation of larger genomes and additional applications and Genomic Expression ha...view more